NHP treatment
toxemia
STERILE, TOXEMIA
Due to the requirements for slow infusion for ANTHRASIL, an ambulatory infusion system (Strategic Applications, Inc., Libertyville, IL, USA) designed for infusion/pharmacokinetic (PK) studies was used. NHPs were individually housed in cages and remained ambulatory during infusion except when placed in a chair intermittently for short periods to change infusion flow rates. The patency of catheter lines and VAPs was maintained by flushing them with heparinized saline. A sterile infusion line was attached to the infusion pump and attached at the other end to a needle inserted into the VAP. As in the rabbit study, toxemia was used as the trigger for treatment on an individual basis. ANTHRASIL was administered at one of three dose levels (7.5, 15 or 30 U/kg), and the placebo was administered at a volume matching that of the 30 U/kg ANTHRASIL group. The infusion durations were approximately 2, 3 and 4.5 and 4.5 hours for the low, mid and high dose ANTHRASIL and IGIV groups, respectively. The ANTHRASIL doses were based on the rabbit dose-time range study, where the same doses were observed to confer significant protection (